Progress toward liver-based gene therapy

Hepatology Research

Volumn 39, Issue 4, 2009, Pages 325-340

  Suda, Takeshi ^a   Kamimura, Kenya ^a,b   Kubota, Tomoyuki ^a   Tamura, Yasushi ^a   Igarashi, Masato ^a   Kawai, Hirokazu ^a   Aoyagi, Yutaka ^a   Liu, Dexi ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Gene therapy; Liver; Non viral vectors; Viral vectors

Indexed keywords

ALPHA FETOPROTEIN; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BETA INTERFERON; BLOOD CLOTTING FACTOR 9; CYTOSINE DEAMINASE; DEATH RECEPTOR; ENDOSTATIN; FLUCYTOSINE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 18; LIPOPLEX; NITROREDUCTASE; NV 1020; ONXY 015; ONYX 015; PHENYLALANINE 4 MONOOXYGENASE; PROTEIN P53; RECOMBINANT INTERLEUKIN 12; RIBOZYME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; CANCER GENE THERAPY; CLINICAL TRIAL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GLYCOGEN STORAGE DISEASE TYPE 2; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPOALPHALIPOPROTEINEMIA; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER; LIVER CANCER; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER STRUCTURE; MONOGENIC DISORDER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIROTHERAPY;

EID: 63649134433     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00479.x     Document Type: Review

References (187)

1. The Journal of Gene Medicine. The Journal of Gene Medicine Clinical Trial site. [Cited 22/12/2008.] Available from URL: http://www.wiley.co.uk/wileychi/genmed/clinical/
2. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-5.
3. Bey H, Abina S, von Kalle C et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-6.
4. US Food and Drug Administration. FDA Statement on Gene Therapy Clinical Trial. [Cited 22/12/2008.] Available from URL: http://www.fda.gov/bbs/ topics/NEWS/2007/NEW01672.html
5. Howe SJ, Mansour MR, Schwarzwaelder K et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-50.
6. Sherlock S, Dooley J. Disease of the Liver and Biliary System. Oxford: Blackwell Publishing Company, 2002.
7. Schiff ER, Sorrell MF, Maddrey WC. Schiff's Diseases of the Liver. Philadelphia, PA: Lippincott Williams & Wilkins, 2007.
8. Burt AD, Portmann BC, Ferrell LD. MacSween's Pathology of the Liver. Philadelphia, PA: Elsevier, 2007.
9. McCuskey RS. The Liver: Biology and Pathobiology. New York: Raven Press, 1994.
10. Nguyen TH, Ferry N. Liver gene therapy: Advances and hurdles. Gene Ther 2004; 11 (Suppl 1): S76-84.
11. Mahato RI, Kawabata K, Takakura Y, Hashida M. In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 1995; 3: 149-57.
12. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004; 78: 5368-81.
13. Zhao H, Friedman RD, Fournier RE. The locus control region activates serpin gene expression through recruitment of liver-specific transcription factors and RNA polymerase II. Mol Cell Biol 2007; 27: 5286-95.
14. Sandig V, Loser P, Lieber A, Kay MA, Strauss M. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Ther 1996; 3: 1002-9.
15. Apollodorus. The Library of Greek Mythology. Oxford: Oxford University Press, 1999.
16. Gao B, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. Hepatology 2008; 47: 729-36.
17. Khorsandi SE, Bachellier P, Weber JC et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther 2008; 15: 225-30.
18. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther 2005; 12: 1089-98.
19. Rettinger SD, Ponder KP, Saylors RL, Kennedy SC, Hafenrichter DG, Flye MW. In vivo hepatocyte transduction with retrovirus during in-flow occlusion. J Surg Res 1993; 54: 418-25.
20. Branchereau S, Calise D, Ferry N. Factors influencing retroviral-mediated gene transfer into hepatocytes in vivo. Hum Gene Ther 1994; 5: 803-8.
21. Lieber A, Vrancken Peeters MJ, Meuse L, Fausto N, Perkins J, Kay MA. Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 6210-14.
22. Borgnon J, Djamouri F, Lorand I et al. Follistatin allows efficient retroviral-mediated gene transfer into rat liver. Biochem Biophys Res Commun 2005; 328: 937-43.
23. Amado RG, Chen IS. Lentiviral vectors - the promise of gene therapy within reach. Science 1999; 285: 674-6.
24. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-17.
25. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-17.
26. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-7.
27. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: A promising tool for gene therapy. Appl Biochem Biotechnol 2006; 133: 9-29.
28. Jager L, Ehrhardt A. Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 2007; 7: 272-83.
29. Peng Z. Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-27.
30. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005; 99: 119-45.
31. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-27.
32. Samulski RJ, Zhu X, Xiao X et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-50.
33. Young SM Jr, McCarty DM, Degtyareva N, Samulski RJ. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 2000; 74: 3953-66.
34. Howden SE, Voullaire L, Vadolas J. The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration. J Gene Med 2007; 10: 42-50.
35. Coura Rdos S, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J 2007; 4: 99.
36. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-40.
37. Altomonte J, Wu L, Chen L et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008; 16: 146-53.
38. Lorence RM, Roberts MS, O'Neil JD et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 2007; 7: 157-67.
39. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 1993; 36: 193-214.
40. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-4.
41. Jarnagin WR, Zager JS, Hezel M et al. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther 2006; 13: 326-34.
42. Thorne SH, Hwang TH, O'Gorman WE et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117: 3350-8.
43. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
44. O'Shea CC, Johnson L, Bagus B et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-23.
45. Liu D, Ren T, Gao X. Cationic transfection lipids. Curr Med Chem 2003; 10: 1307-15.
46. Byk G, Dubertret C, Escriou V et al. Synthesis, activity, and structure - activity relationship studies of novel cationic lipids for DNA transfer. J Med Chem 1998; 41: 229-35.
47. Liu F, Qi H, Huang L, Liu D. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther 1997; 4: 517-23.
48. Song YK, Liu F, Chu S, Liu D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum Gene Ther 1997; 8: 1585-94.
49. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-301.
50. Haensler J, Szoka FC Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993; 4: 372-9.
51. Tang MX, Redemann CT, Szoka FC Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 1996; 7: 703-14.
52. Rudolph C, Lausier J, Naundorf S, Muller RH, Rosenecker J. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med 2000; 2: 269-78.
53. Schatzlein AG, Zinselmeyer BH, Elouzi A et al. Preferential liver gene expression with polypropylenimine dendrimers. J Control Release 2005; 101: 247-58.
54. Hosseinkhani H, Azzam T, Tabata Y, Domb AJ. Dextran-spermine polycation: an efficient non-viral vector for in vitro and in vivo gene transfection. Gene Ther 2004; 11: 194-203.
55. Leong KW, Mao HQ, Truong Le VL, Roy K, Walsh SM, August JT. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998; 53: 183-93.
56. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability. Pharm Res 1998; 15: 1332-9.
57. Balicki D, Reisfeld RA, Pertl U, Beutler E, Lode HN. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. Proc Natl Acad Sci USA 2000; 97: 11500-4.
58. Park YJ, Liang JF, Ko KS, Kim SW, Yang VC. Low molecular weight protamine as an efficient and nontoxic gene carrier: In vitro study. J Gene Med 2003; 5: 700-11.
59. Audouy SA, de Leij LF, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002; 19: 1599-605.
60. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002; 4: 84-91.
61. Plank C, Mechtler K, Szoka FC Jr, Wagner E. Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. Hum Gene Ther 1996; 7: 1437-46.
62. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochem 1996; 35: 1027-36.
63. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997; 4: 961-8.
64. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997; 4: 891-900.
65. Lee LK, Williams CL, Devore D, Roth CM. Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules 2006; 7: 1502-8.
66. Wolschek MF, Thallinger C, Kursa M et al. Specific systemic non-viral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 2002; 36: 1106-14.
67. Takei Y, Maruyama A, Ferdous A et al. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx. FASEB J 2004; 18: 699-701.
68. Erbacher P, Remy JS, Behr JP. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther 1999; 6: 138-45.
69. Kircheis R, Wightman L, Schreiber A et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther 2001; 8: 28-40.
70. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002; 54: 675-93.
71. Kawakami S, Yamashita F, Nishida K, Nakamura J, Hashida M. Glycosylated cationic liposomes for cell-selective gene delivery. Crit Rev Ther Drug Carrier Syst 2002; 19: 171-90.
72. Tan PH, Manunta M, Ardjomand N et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003; 5: 311-23.
73. Ma N, Wu SS, Ma YX et al. Nerve growth factor receptor-mediated gene transfer. Mol Ther 2004; 9: 270-81.
74. Barrett LB, Berry M, Ying WB et al. CTb targeted non-viral cDNA delivery enhances transgene expression in neurons. J Gene Med 2004; 6: 429-38.
75. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-4.
76. Kim KS, Lei Y, Stolz DB, Liu D. Bifunctional compounds for targeted hepatic gene delivery. Gene Ther 2007; 14: 704-8.
77. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
78. Furth PA, Kerr D, Wall R. Gene transfer by jet injection into differentiated tissues of living animals and in organ culture. Mol Biotechnol 1995; 4: 121-7.
79. Jaichandran S, Yap ST, Khoo AB, Ho LP, Tien SL, Kon OL. In vivo liver electroporation: Optimization and demonstration of therapeutic efficacy. Hum Gene Ther 2006; 17: 362-75.
80. Anwer K, Kao G, Proctor B et al. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther 2000; 7: 1833-9.
81. Widder KJ, Senyel AE, Scarpelli GD. Magnetic microspheres: A model system of site specific drug delivery in vivo. Proc Soc Exp Biol Med 1978; 158: 141-6.
82. Zeira E, Manevitch A, Manevitch Z et al. Femtosecond laser: A new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. FASEB J 2007; 21: 3522-33.
83. Walther W, Stein U, Fichtner I, Malcherek L, Lemm M, Schlag PM. Non-viral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther 2001; 8: 173-80.
84. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990; 87: 9568-72.
85. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-7.
86. Mitragotri S, Edwards DA, Blankschtein D, Langer R. A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci 1995; 84: 697-706.
87. Huth S, Lausier J, Gersting SW etal. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004; 6: 923-36.
88. Neumann E, Schaefer Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-5.
89. Zeira E, Manevitch A, Khatchatouriants A et al. Femtosecond infrared laser-an efficient and safe in vivo gene delivery system for prolonged expression. Mol Ther 2003; 8: 342-50.
90. Berg K, Selbo PK, Prasmickaite L et al. Photochemical internalization: A novel technology for delivery of macromolecules into cytosol. Cancer Res 1999; 59: 1180-3.
91. Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001; 8: 827-34.
92. Cho Rok J, Yoo J, Jang YJ etal. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006; 43: 1042-52.
93. Zender L, Kock R, Eckhard M et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002; 123: 608-18.
94. Yoshikawa H, Matsubara K, Qian GS et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
95. Zhang M, Li S, Nyati MK et al. Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model. Cancer Res 2003; 63: 658-63.
96. Faivre J, Clerc J, Gerolami R et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 2004; 64: 8045-51.
97. Kunitomi M, Takayama E, Suzuki S et al. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/ enhancer region of the human alpha-fetoprotein gene. Jpn J Cancer Res 2000; 91: 343-50.
98. Jacob D, Schumacher G, Bahra M et al. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells. World J Gastroenterol 2005; 11: 2552-6.
99. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003; 22: 9087-96.
100. Li H, Fu X, Chen Y et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128: 2029-41.
101. Chen Y, Lin MC, Yao H et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007; 46: 200-8.
102. Huesker M, Folmer Y, Schneider M, Fulda C, Blum HE, Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology 2002; 36: 874-84.
103. Li N, Zhou J, Weng D et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13: 5847-54.
104. Kuriyama S, Mitoro A, Yamazaki M et al. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand J Gastroenterol 1999; 34: 1033-41.
105. Andrews KJ, Ribas A, Butterfield LH et al. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res 2000; 60: 6457-64.
106. Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541-8.
107. Barajas M, Mazzolini G, Genove G et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33: 52-61.
108. Waehler R, Ittrich H, Mueller L, Krupski G, Ameis D, Schnieders F. Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12. Hum Gene Ther 2005; 16: 307-17.
109. Ma H, Liu Y, Liu S, Xu R, Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005; 42: 1355-63.
110. Grimm CF, Ortmann D, Mohr L et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 2000; 119: 1104-12.
111. Meng WS, Butterfield LH, Ribas A et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001; 61: 8782-6.
112. Cao DY, Yang JY, Dou KF, Ma LY, Teng ZH. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in vitro. Hum Immunol 2007; 68: 334-41.
113. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006; 66: 7694-700.
114. Bucheit AD, Kumar S, Grote DM et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62-72.
115. Nakamura T, Peng KW, Harvey M et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209-14.
116. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther 2007; 18: 837-48.
117. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target 2007; 15: 546-51.
118. Tsai KL, Clark LA, Murphy KE. Understanding hereditary diseases using the dog and human as companion model systems. Mamm Genome 2007; 18: 444-51.
119. Merle U, Encke J, Tuma S, Volkmann M, Naldini L, Stremmel W. Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats: An animal model for Wilson disease. Scand J Gastroenterol 2006; 41: 974-82.
120. Ghosh A, Allamarvdasht M, Pan CJ et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther 2006; 13: 321-9.
121. Yiu WH, Pan CJ, Allamarvdasht M, Kim SY, Chou JY. Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice. Gene Ther 2007; 14: 219-26.
122. Kobayashi H, Carbonaro D, Pepper K et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 2005; 11: 776-89.
123. Di Natale P, Di Domenico C, Gargiulo N et al. Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector. Biochem J 2005; 388: 639-46.
124. Ponder KP, Melniczek JR, Xu L et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 2002; 99: 13102-7.
125. Overturf K, Al Dhalimy M, Tanguay R et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996; 12: 266-73.
126. Seppen J, van der Rijt R, Looije N, van Til NP, Lamers WH, Oude Elferink RP. Long-term correction of bilirubin UDP glucuronyltransferase deficiency in rats by in utero lentiviral gene transfer. Mol Ther 2003; 8: 593-9.
127. Miao CH, Thompson AR, Loeb K, Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-57.
128. Ye X, Loeb KR, Stafford DW, Thompson AR, Miao CH. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid. J Thromb Haemost 2003; 1: 103-11.
129. Herzog RW, Yang EY, Couto LB et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
130. Ye P, Thompson AR, Sarkar R et al. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther 2004; 10: 117-26.
131. Waddington SN, Nivsarkar MS, Mistry AR et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 2004; 104: 2714-21.
132. Pauly DF, Fraites TJ, Toma C et al. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Hum Gene Ther 2001; 12: 527-38.
133. Sun B, Zhang H, Franco LM et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005; 11: 57-65.
134. Sondergaard M, Dagnaes-Hansen F, Flyvbjerg A, Jensen TG. Normalization of growth in hypophysectomized mice using hydrodynamic transfer of the human growth hormone gene. Am J Physiol Endocrinol Metab 2003; 285: E427-32.
135. Chen L, Woo SL. Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA. Proc Natl Acad Sci USA 2005; 102: 15581-6.
136. Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML. Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998; 21 (Suppl 1): 119-37.
137. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46: 872-84.
138. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282-7.
139. Oka K, Belalcazar LM, Dieker C et al. Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. Gene Ther 2007; 14: 191-202.
140. McCaffrey AP, Nakai H, Pandey K et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-44.
141. McCaffrey AP, Meuse L, Pham T-TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418: 38-9.
142. Kronke J, Kittler R, Buchholz F et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 2004; 78: 3436-46.
143. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-81.
144. Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther 2008; 16: 1105-12.
145. Birmingham A, Anderson EM, Reynolds A et al. 3′UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3: 199-204.
146. Song E, Lee S-K, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-51.
147. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-51.
148. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
149. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999; 96: 12719-24.
150. Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-30.
151. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7: D1720-6.
152. Tsui TY, Lau CK, Ma J et al. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: A new approach to attenuate liver fibrosis in rats. Hepatology 2005; 42: 335-42.
153. Salgado S, Garcia J, Vera J et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000; 2: 545-51.
154. Sato Y, Murase K, Kato J et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008; 26: 431-42.
155. Chu Y, Iida S, Lund DD et al. Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: role of heparin-binding domain. Circ Res 2003; 92: 461-8.
156. Iida S, Chu Y, Francis J et al. Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure. Am J Physiol Heart Circ Physiol 2005; 289: H525-32.
157. Palmer DH, Mautner V, Mirza D et al. Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546-52.
158. Sangro B, Mazzolini G, Ruiz J et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-97.
159. Habib NA, Hodgson HJ, Lemoine N, Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 1999; 10: 2019-34.
160. Sung MW, Yeh HC, Thung SN et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol Ther 2001; 4: 182-91.
161. Rubin J, Galanis E, Pitot HC etal. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4: 419-25.
162. Stopeck AT, Jones A, Hersh EM et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/ beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7: 2285-91.
163. Lin X, Huang H, Li S et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007; 6: 648-53.
164. Manno CS, Pierce GF, Arruda VR et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-7.
165. Raper SE, Yudkoff M, Chirmule N et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-75.
166. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
167. Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35.
168. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and Anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-42.
169. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-5 9 4, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 2008; 9: 533-42.
170. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005; 12: 673-81.
171. Donsante A, Miller DG, Li Y et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317: 477.
172. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316-24.
173. Sabatino DE, Mackenzie TC, Peranteau W et al. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. Mol Ther 2007; 15: 1677-85.
174. Tominaga K, Kuriyama S, Yoshiji H et al. Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies. Gut 2004; 53: 1167-73.
175. Gao G, Lu Y, Calcedo R et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
176. Overturf K, Al Dhalimy M, Ou CN et al. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 1997; 8: 513-21.
177. Grompe M, Overturf K, al Dhalimy M, Finegold M. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report. J Inherit Metab Dis 1998; 21: 518-31.
178. Jacobs P. Doctor tried gene therapy on two humans. Washington Post 1980; A1: A15.
179. Alba R, Bosch A, Chillon M. Gutless adenovirus: Last-generation adenovirus for gene therapy. Gene Ther 2005; 12 (Suppl 1): S18-27.
180. Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: Challenges and prospects. Curr Gene Ther 2007; 7: 297-305.
181. Brunetti Pierri N, Ng P. Progress and prospects: Gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 2008; 15: 553-60.
182. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953; 84: 570-3.
183. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965; 149: 754-6.
184. Evans RK, Nawrocki DK, Isopi LA et al. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 2004; 93: 2458-75.
185. Suda T, Liu D. Non-viral gene delivery system. In: Dropulic B, Carter B, eds. Concepts in Genetic Medicine, 1st edn. Hoboken, NJ: Wiley, 2008; 103-22.
186. Suda T, Suda K, Liu D. Computer-assisted Hydrodynamic Gene Delivery. Mol Ther 2008; 16: 1098-104.
187. Powell JS, Ragni MV, White GC II et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102: 2038-45.